المؤلفون: Fischer L; Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany. luca.fischer@med.uni-muenchen.de., Jiang L; Institute for Medical Information Processing, Biometry and Epidemiology, LMU Munich, Munich, Germany., Dürig J; Internal Medicine, St. Josef Hospital, Essen-Werden, Germany., Schmidt C; Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany., Stilgenbauer S; Klinik für Innere Medizin III, Ulm University-Medical Center, Ulm, Germany., Bouabdallah K; Department of Hematology and Cellular Therapy, University Hospital of Bordeaux, F-33000, Bordeaux, France., Solal-Celigny P; Institut de Cancérologie de l'Ouest, Saint-Herblain, Bld Jacques Monod, 44805, Saint-Herblain, Cedex, France., Scholz CW; Department of Hematology and Oncology, Vivantes Klinikum Am Urban, Berlin, Germany., Feugier P; Service d'Hématologie et Medecine Interne, Centre Hospitalier Universitaire Nancy-Brabois, Vandoeuvre, France., de Wit M; Klinik für Innere Medizin, Hämatologie, Onkologie und Palliativmedizin, Vivantes Klinikum Neukölln, Berlin, Germany., Trappe RU; Department of Hematology and Oncology, DIAKO Ev. Diakonie-Krankenhaus, Bremen, Germany., Hallek M; Department I for Internal Medicine and Centre of Integrated Oncology Aachen, Bonn, Cologne, Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany., Graeven U; Department for Hematology, Oncology and Gastroenterology, Kliniken Maria-Hilf Mönchengladbach, Mönchengladbach, Germany., Hänel M; Department of Internal Medicine III, Klinikum Chemnitz, Chemnitz, Germany., Hoffmann M; Medizinische Klinik A, Klinikum der Stadt Ludwigshafen gGmbH, Ludwigshafen, Germany., Delwail V; CHU Poitiers, Poitiers, France., Macro M; Hematology Department, University Hospital, Caen, France., Greiner J; Department. of Internal Medicine, Diakonie-Hospital Stuttgart, 70176, Stuttgart, Germany., Giagounidis AAN; Marien Hospital Düsseldorf, Düsseldorf, 40479, Germany., Dargel B; Medical Center Harz GmbH, Wernigerode, Germany., Durot E; CHU Reims, Hématologie Clinique, F-51100, Reims, France., Foussard C; Department of Pathology, Centre Hospitalier, 49100, Angers, France., Silkenstedt E; Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany., Weigert O; Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany., Pott C; Department of Internal Medicine II: Hematology and Oncology, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany., Klapper W; Hematopathology Section, Christian-Albrechts University, Kiel, Germany., Hiddemann W; Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany., Unterhalt M; Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany., Hoster E; Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany.; Institute for Medical Information Processing, Biometry and Epidemiology, LMU Munich, Munich, Germany., Ribrag V; Gustave Roussy, Université Paris-Saclay, DITEP, INSERM U1170, Villejuif, France., Dreyling M; Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany.

المصدر: Leukemia [Leukemia] 2024 Jun; Vol. 38 (6), pp. 1307-1314. Date of Electronic Publication: 2024 Apr 27.

نوع المنشور: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study

بيانات الدورية: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE

مواضيع طبية MeSH: Bortezomib*/administration & dosage , Bortezomib*/therapeutic use , Lymphoma, Mantle-Cell*/drug therapy , Lymphoma, Mantle-Cell*/pathology , Lymphoma, Mantle-Cell*/mortality , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Dexamethasone*/administration & dosage , Dexamethasone*/therapeutic use , Dexamethasone*/adverse effects , Cytarabine*/administration & dosage , Cytarabine*/therapeutic use , Rituximab*/administration & dosage , Rituximab*/therapeutic use , Neoplasm Recurrence, Local*/drug therapy , Neoplasm Recurrence, Local*/pathology, Humans ; Female ; Male ; Aged ; Middle Aged ; Adult ; Drug Resistance, Neoplasm ; Survival Rate ; Aged, 80 and over ; Follow-Up Studies